Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer

por Zardan, A, Nip, K M, Thaper, D, Toren, P, Vahid, S, Beraldi, E, Fazli, L, Lamoureux, F, Gust, K M, Cox, M E, Bishop, J L, Zoubeidi, A
Publicado 2014

DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis

por Zhou, J, Ning, Z, Wang, B, Yun, E-J, Zhang, T, Pong, R-C, Fazli, L, Gleave, M, Zeng, J, Fan, J, Wang, X, Li, L, Hsieh, J-T, He, D, Wu, K
Publicado 2015

Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality

por Tse, B W C, Volpert, M, Ratther, E, Stylianou, N, Nouri, M, McGowan, K, Lehman, M L, McPherson, S J, Roshan-Moniri, M, Butler, M S, Caradec, J, Gregory-Evans, C Y, McGovern, J, Das, R, Takhar, M, Erho, N, Alshalafa, M, Davicioni, E, Schaeffer, E M, Jenkins, R B, Ross, A E, Karnes, R J, Den, R B, Fazli, L, Gregory, P A, Gleave, M E, Williams, E D, Rennie, P S, Buttyan, R, Gunter, J H, Selth, L A, Russell, P J, Nelson, C C, Hollier, B G
Publicado 2017